Prodrug derivatives of protein kinase C modulators

US11370743B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Paul A. Wender · Menlo Park, US
• Katherine N. Keenan · Stanford, US
• Nancy Benner · Stanford, US
• Jack Sloane · Stanford, US
• Xiaoyu Zang · Stanford, US

Key dates

• Filing date: May 10, 2018
• Grant date: Jun 28, 2022
• Expiry date: Oct 23, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2603/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Embodiments of prodrugs of PKC modulators that show efficacy coupled with low levels of toxicity and improved stability are provided. The prodrug compounds are useful in academic research (animal studies), as candidates for preclinical research, and as therapeutic agents. By taking advantage of a pharmacophore-based strategy, this design strategy provides access to prodrugs of PKC modulators of diverse scaffolds including tigliane diterpenes, ingenane diterpenes, daphnane diterpene orthoesters, diacylglycerols, and bryostatins, and analogs thereof. In particular, embodiments of the prodrug ingenane esters having substitutions at C20 and their use as therapeutic agents are provided.